Table 2.
Change in prednisone use at 6 and 12 months by prednisone dose at baseline
| All patientsa | Prednisone at TCZ initiation | |||
|---|---|---|---|---|
| Not receiving prednisone | Prednisone dose ≤ 7.5 mg | Prednisone dose > 7.5 mg | ||
| 6 months | ||||
| All patients with a 6-month visit | 541 | 356 | 107 | 78 |
| No change in prednisone dose, n (%)b | 426 (78.7) | 327 (91.9) | 67 (62.6) | 32 (41.0) |
| Increased dose by ≥ 5 mg, n (%) | 39 (7.2) | 29 (8.1) | 4 (3.7) | 6 (7.7) |
| Decreased dose by ≥ 5 mg, n (%)c | 21 (3.9) | 0 | 1 (0.9) | 20 (25.6) |
| Stopped prednisone, n (%) | 55 (10.2) | 0 | 35 (32.7) | 20 (25.6) |
| 12 months | ||||
| All patients with a 12-month visit | 648 | 426 | 130 | 92 |
| No change in prednisone dose, n (%)b | 505 (77.9) | 390 (91.5) | 84 (64.6) | 31 (33.7) |
| Increased dose by ≥ 5 mg, n (%) | 46 (7.1) | 36 (8.5) | 7 (5.4) | 3 (3.3) |
| Decreased dose by ≥ 5 mg, n (%)c | 29 (4.5) | 0 | 1 (0.8) | 28 (30.4) |
| Stopped prednisone, n (%) | 68 (10.5) | 0 | 38 (29.2) | 30 (32.6) |
TCZ tocilizumab
aWith a visit at 6 or 12 months
bAlso includes those with < 5 mg change in prednisone dose
cDoes not include patients who discontinued prednisone